# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-19-046127
Filing Date
2019-09-27
Accepted
2019-09-27 06:01:06
Documents
3
Period of Report
2019-10-28
Effectiveness Date
2019-09-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | tv529609-def14a.htm | DEF 14A | 249066
2 | GRAPHIC | tv529467_pc1.jpg | GRAPHIC | 507403
3 | GRAPHIC | tv529467_pc2.jpg | GRAPHIC | 492165
| Complete submission text file | 0001144204-19-046127.txt |  | 1626656

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 191119502
SIC: 2834 Pharmaceutical Preparations